AOD9604 Peptide Guide: The Fat-Burning Research Compound
In the crowded landscape of metabolic research, most compounds take a familiar approach: suppress appetite, slow digestion, or stimulate insulin.
AOD9604 is different.
Originally derived from human growth hormone (HGH), AOD9604 isolates the fat-burning fragment of HGH โ without any of the growth-related side effects. This means researchers can study lipolysis (fat breakdown) and metabolism without affecting muscle growth, organ size, or blood sugar regulation.
Let’s dive into the science.
What Is AOD9604?
AOD9604 is a synthetic peptide fragment derived from the C-terminal end of human growth hormone (HGH) โ specifically amino acids 177-191. Unlike full-length HGH, AOD9604 retains the lipolytic (fat-burning) properties of HGH while having no effect on:
- IGF-1 levels (no growth stimulation)
- Blood sugar (no hyperglycemic effect)
- Organ size (no organomegaly)
- Muscle growth (no anabolic effects)
| Feature | Detail |
|---|---|
| Full Name | AOD9604 (Anti-Obesity Drug 9604) |
| Type | Synthetic peptide fragment (HGH 177-191) |
| Origin | Derived from human growth hormone |
| Primary Research Areas | Lipolysis, fat oxidation, metabolic health |
| Key Property | Fat-burning without HGH side effects |
Developed by Metabolic Pharmaceuticals, AOD9604 completed Phase II clinical trials for obesity before being licensed for research applications worldwide.
How Does AOD9604 Work?
AOD9604’s mechanism of action is distinct from both full-length HGH and GLP-1 agonists.
1. Lipolysis Activation
The primary effect of AOD9604 is stimulating lipolysis โ the breakdown of fat stores into free fatty acids:
- Activates hormone-sensitive lipase (HSL)
- Increases cyclic AMP (cAMP) signaling in fat cells
- Promotes the release of stored triglycerides
- lipolysis mechanisms
Unlike stimulants that increase catecholamines (adrenaline), AOD9604 works directly on adipose tissue through a non-ฮฒ-adrenergic pathway โ meaning no jitters, increased heart rate, or blood pressure elevation.
2. Fat Oxidation
Beyond breaking down fat, AOD9604 enhances the body’s ability to burn that fat for energy:
- Increases fatty acid oxidation in mitochondria
- Improves metabolic flexibility
- May enhance exercise-induced fat burning
3. Thermogenesis
Preliminary research suggests AOD9604 may modestly increase thermogenesis โ the production of heat from burning calories. While not a dramatic effect, it contributes to overall metabolic rate.
4. No Effect on Appetite or Blood Sugar
Unlike GLP-1 agonists (semaglutide, tirzepatide, retatrutide), AOD9604:
- Does not suppress appetite
- Does not affect gastric emptying
- Does not lower blood sugar
This makes AOD9604 fundamentally different from the current generation of weight management peptides. It targets fat directly rather than reducing food intake.
Key Research Areas
Obesity & Body Composition
AOD9604 has been studied primarily for obesity and body composition:
- Phase II clinical trials showed statistically significant fat loss compared to placebo
- Reduced waist circumference and total body fat percentage
- Preserved lean mass during weight loss
- AOD9604 clinical trials
One study found that after 12 weeks, subjects taking AOD9604 lost significantly more body fat than those on placebo โ without diet or exercise changes.
Metabolic Health
Research suggests AOD9604 may improve metabolic parameters:
- Improved lipid profiles (reduced triglycerides, improved HDL/LDL ratio)
- Enhanced insulin sensitivity (through reduced fat stores rather than direct effect)
- Reduced visceral adipose tissue (the most metabolically harmful fat)
Exercise Performance & Recovery
While not a direct performance enhancer, AOD9604 may support:
- Increased fat utilization during exercise (sparing glycogen)
- Reduced exercise-induced inflammation
- Improved recovery markers
For researchers studying metabolism and exercise, AOD9604 offers a unique tool to investigate fat oxidation separate from appetite effects.
Adipose Tissue Research
AOD9604 is valuable for studying fundamental questions about fat metabolism:
- Mechanisms of lipolysis regulation
- Adipocyte signaling pathways
- Differences between subcutaneous and visceral fat
- adipose tissue research
AOD9604 vs. GLP-1 Agonists
| Feature | AOD9604 | Retatrutide (Triple Agonist) | Semaglutide |
|---|---|---|---|
| Primary Mechanism | Direct lipolysis | Appetite suppression + metabolism | Appetite suppression |
| Appetite Effect | None | Significant | Significant |
| Blood Sugar Effect | None | Significant reduction | Significant reduction |
| Side Effect Profile | Mild (injection site) | GI (nausea, constipation) | GI (nausea, vomiting) |
| Muscle Preservation | Yes (preserves lean mass) | Variable (rapid loss can include muscle) | Variable |
| Research Focus | Fat metabolism, body composition | Obesity, diabetes, metabolic health | Obesity, diabetes |
Stacking Potential
Because AOD9604 and GLP-1 agonists work through completely different mechanisms, researchers are exploring whether they could be complementary:
- GLP-1 agonist โ Reduces appetite, slows digestion
- AOD9604 โ Directly increases fat burning
However, stacking research is preliminary and requires careful protocol design.
Practical Considerations for Researchers
Form & Administration
AOD9604 is typically supplied as:
| Form | Best For |
|---|---|
| Lyophilized powder | Subcutaneous injection research |
| Solution | Ready-to-use for laboratory applications |
Typical Research Protocols
| Parameter | Typical Range |
|---|---|
| Dosage | 200-500mcg per injection |
| Frequency | 1-2 times daily |
| Cycle Length | 30-60 days |
| Administration | Subcutaneous injection (abdomen or thigh) |
Reconstitution
- Use bacteriostatic water (not saline or sterile water alone)
- Gently swirl โ do not shake
- Refrigerate after reconstitution
- Use within 30 days
Storage
- Store lyophilized powder in the refrigerator (2-8ยฐC) or freezer (-20ยฐC)
- Protect from light
- Do not freeze after reconstitution
What AOD9604 Is NOT
Let’s clear up some common misconceptions:
- Not an appetite suppressant: AOD9604 doesn’t reduce hunger or food intake
- Not a stimulant: No jitters, anxiety, or increased heart rate
- Not growth hormone: No effect on IGF-1, muscle growth, or organ size
- Not a quick fix: Fat loss occurs over weeks, not days
- Not a substitute for diet and exercise: Effects are additive, not replacements
Safety & Research Status
AOD9604 has been studied in Phase II clinical trials involving hundreds of subjects:
- Well-tolerated with mild side effects primarily at injection site
- No serious adverse events attributed to the compound
- No effect on blood sugar (important for non-diabetic research)
- No evidence of cardiac effects (unlike some stimulant-based fat burners)
The compound was licensed for research worldwide after demonstrating safety in human trials. It’s important to note that AOD9604 was not approved by the FDA for commercial weight loss โ not due to safety concerns, but because the company shifted focus to other research priorities.
All AOD9604 is intended for laboratory research only.
The Bottom Line
AOD9604 represents a unique approach to fat metabolism research. Instead of reducing calorie intake (through appetite suppression) or increasing calorie output (through stimulants), it works by:
- โ Directly stimulating lipolysis (fat breakdown)
- โ Enhancing fat oxidation (burning fat for energy)
- โ Preserving lean mass during weight loss
- โ No appetite or blood sugar effects
For researchers studying obesity, body composition, metabolic health, or adipose tissue biology, AOD9604 offers a well-characterized, clinically-studied tool with a mechanism entirely distinct from GLP-1 agonists.
Want to Learn More?
If you’re interested in researching AOD9604, we offer HPLC-verified AOD9604 for laboratory use only. Each batch is tested for purity and comes with a Certificate of Analysis.
[Shop AOD9604 โ]
For research use only. Not for human consumption or medical use.
Have questions about AOD9604 or fat-burning peptides? Drop a comment below or reach out to our team.
